Melanoma Therapeutics Market to grow 16.6%, to 2019 New Research

Piribo, the online destination for Pharma intelligence, has added a new report.

The report “Melanoma Therapeutics: Pipeline Assessment and Market Forecasts to 2019” available at identifies the key trends shaping and driving the global melanoma therapeutics market. It also provides valuable insights on the pipeline products within the global melanoma therapeutics sector.

According to the 138 page report the global melanoma therapeutics market was valued at $0.8 billion in 2011, after growing  22.8% during 2006-2011. During 2011-2019, the market is expected to record a CAGR of 16.6%, from $0.8 billion in 2011 to $2.6 billion in 2019.

The current treatment options for melanoma include –

  • Adjuvant therapies such as Intron-A (interferon alfa-2b) and Sylatron(peg-interferon alfa-2b)
  • Newly approved targeted therapies such as Yervoy(ipilimumab) and Zelboraf(vemurafenib)
  • Immunotherapy such as Proleukin(aldesleukin)
  • Cytotoxics such as dacarbazine and other off-label drugs including temozolomide, cisplatin and paclitaxel.

View more Diseases Market Research at, the source for information products concerning the global biotechnology and pharmaceutical industries. Here you can browse and buy thousands of business information studies, market reports and books. Piribo has ongoing relationships with leading market research and publishing companies, so we can offer you a current and comprehensive range of specialised intelligence.

t. 44 (0) 20 7060 7474 is the source for information products concerning the global biotechnology, healthcare, medical device and pharmaceutical industries. With over 26,000 market reports available, executives can find a current and comprehensive range of specialised intelligence. is a service from Piribo Ltd, which was founded in 2004.


About Us is the intelligent way to find and buy business information products. We serve all sizes of companies, from the early stage start-up to global corporations across all sectors and markets.